

# Martin H Fenner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7860329/publications.pdf>

Version: 2024-02-01

52  
papers

2,819  
citations

279798

23  
h-index

233421

45  
g-index

498  
all docs

498  
docs citations

498  
times ranked

3430  
citing authors

#	ARTICLE	IF	CITATIONS
1	Connected Research: The Potential of the PID Graph. <i>Patterns</i> , 2021, 2, 100180.	5.9	24
2	Open Science Graphs Must Interoperate!. <i>Communications in Computer and Information Science</i> , 2020, , 195-206.	0.5	5
3	A data citation roadmap for scholarly data repositories. <i>Scientific Data</i> , 2019, 6, 28.	5.3	59
4	Connecting Researchers to Data Repositories in the Earth, Space, and Environmental Sciences. <i>Communications in Computer and Information Science</i> , 2019, , 86-96.	0.5	3
5	Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 717-723.	2.5	25
6	The Scholix Framework for Interoperability in Data-Literature Information Exchange. <i>D-Lib Magazine</i> , 2017, 23, .	0.5	37
7	Altmetrics and Other Novel Measures for Scientific Impact. , 2014, , 179-189.		39
8	Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO 31/05). <i>BJU International</i> , 2014, 113, 429-436.	2.5	72
9	Unique Identifiers for Researchers. , 2014, , 293-296.		6
10	A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer (RADIT).. <i>Journal of Clinical Oncology</i> , 2014, 32, e15535-e15535.	1.6	1
11	Reference Management. , 2014, , 125-137.		5
12	Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5084-5084.	1.6	0
13	PlosOpenR " Exploring FP7 funded PLOS publications. <i>Information Services and Use</i> , 2013, 33, 93-101.	0.2	1
14	What Can Article-Level Metrics Do for You?. <i>PLoS Biology</i> , 2013, 11, e1001687.	5.6	66
15	Letter from the Guest Content Editor: Altmetrics Have Come of Age. <i>Information Standards Quarterly</i> , 2013, 25, 3.	0.3	6
16	Altmetrics in Evolution: Defining and Redefining the Ontology of Article-Level Metrics. <i>Information Standards Quarterly</i> , 2013, 25, 20.	0.3	73
17	Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 152-152.	1.6	0
18	Effectiveness of abiraterone as salvage therapy in patients with docetaxel- and castration-resistant prostate cancer (mDCPC) that progressed during second-line chemotherapy with carboplatin plus weekly docetaxel (DC).. <i>Journal of Clinical Oncology</i> , 2013, 31, e16064-e16064.	1.6	0

#	ARTICLE	IF	CITATIONS
19	ORCID: a system to uniquely identify researchers. <i>Learned Publishing</i> , 2012, 25, 259-264.	1.7	190
20	Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2012, 48, 1023-1030.	2.8	46
21	Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST). <i>BMC Cancer</i> , 2012, 12, 186.	2.6	16
22	One-click science marketing. <i>Nature Materials</i> , 2012, 11, 261-263.	27.5	11
23	Efficacy of Sunitinib Re-Exposure after Failure of an mTOR Inhibitor in Patients with Metastatic RCC. <i>Onkologie</i> , 2011, 34, 310-314.	0.8	36
24	Retrospective Analyses of Patient Characteristics Having Predictive Impact on Survival under Everolimus. <i>Onkologie</i> , 2011, 34, 111-114.	0.8	4
25	Key Issue & Collective Action for the Open Researcher & Contributor ID (ORCID). <i>Serials</i> , 2011, 24, 277-279.	0.5	5
26	New Systemic Therapies for Refractory Tumors. , 2011, , 253-261.		0
27	Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer. <i>World Journal of Urology</i> , 2010, 28, 391-398.	2.2	18
28	Complete cytogenetic remission after decitabine treatment in a patient with secondary AML harbouring high p15 INK4b gene methylation and high global DNA methylation. <i>Annals of Hematology</i> , 2009, 88, 275-277.	1.8	2
29	Duplication: stop favouring applicant with longest list. <i>Nature</i> , 2008, 452, 29-29.	27.8	2
30	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. <i>European Urology</i> , 2008, 53, 478-496.	1.9	488
31	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. <i>European Urology</i> , 2008, 53, 497-513.	1.9	243
32	Targeted therapies for patients with germ cell tumors. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 511-522.	4.1	18
33	Erythropoietin in cancer-related anemia. <i>Current Opinion in Oncology</i> , 2008, 20, 685-689.	2.4	8
34	Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPAR $\alpha/\beta$ ligand TZD18. <i>Blood</i> , 2006, 107, 3683-3692.	1.4	57
35	Peroxisome proliferator-activated receptor- $\beta$ ligands for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 557-568.	4.1	74
36	Peroxisome proliferator-activated receptor $\beta$ ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia. <i>Leukemia Research</i> , 2004, 28, 387-397.	0.8	41

#	ARTICLE	IF	CITATIONS
37	Induction of Growth Inhibition and Apoptosis by TZD18, a Novel Dual Ligand for PPAR alpha/gamma, in Human Ph-Positive ALL Cells In Vitro.. Blood, 2004, 104, 2088-2088.	1.4	0
38	PPAR $\gamma$ Ligands and ATRA Inhibit the Invasion of Human Breast Cancer Cells in vitro. Breast Cancer Research and Treatment, 2003, 79, 63-74.	2.5	140
39	Ligands for PPAR $\gamma$ and RAR Cause Induction of Growth Inhibition and Apoptosis in Human Glioblastomas. Journal of Neuro-Oncology, 2003, 65, 107-118.	2.9	52
40	Chemotherapy for Breast Cancer Brain Metastases. Oncology Research and Treatment, 2002, 25, 474-479.	1.2	23
41	Novel Therapeutic Approach: Ligands for PPAR $\gamma$ and Retinoid Receptors Induce Apoptosis in bcl-2-positive Human Breast Cancer Cells. Breast Cancer Research and Treatment, 2002, 74, 155-165.	2.5	80
42	X Inactivation in the Mouse Embryo Deficient for Dnmt1: Distinct Effect of Hypomethylation on Imprinted and Random X Inactivation. Developmental Biology, 2000, 225, 294-303.	2.0	242
43	Regulation of Expression of MSG1 Melanocyte-Specific Nuclear Protein in Human Melanocytes and Melanoma Cells. Experimental Cell Research, 1998, 242, 478-486.	2.6	22
44	MSG1(Melanocyte-Specific Gene 1): Mapping to Chromosome Xq13.1, Genomic Organization, and Promoter Analysis. Genomics, 1998, 51, 401-407.	2.9	24
45	Transcriptional activating activity of Smad4: Roles of SMAD hetero-oligomerization and enhancement by an associating transactivator. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9785-9790.	7.1	122
46	Experimental animal model of hematogenous cardiac metastasis and neoplastic cardiac tamponade. Journal of Surgical Oncology, 1997, 64, 122-126.	1.7	1
47	MSG1 and its related protein MRG1 share a transcription activating domain. Gene, 1997, 204, 235-241.	2.2	51
48	msg1, a novel melanocyte-specific gene, encodes a nuclear protein and is associated with pigmentation.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 12298-12303.	7.1	81
49	Hepatic and Serologic Toxicity of Systemic Interleukin-2 and/or Interferon- $\gamma$ . American Journal of Clinical Oncology: Cancer Clinical Trials, 1994, 17, 199-209.	1.3	11
50	Lack of therapeutic efficacy of tamoxifen in advanced renal cell carcinoma. European Journal of Cancer, 1993, 29, 737-740.	2.8	16
51	Interleukin-2 in combination with interferon- $\gamma$ and 5-fluorouracil for metastatic renal cell cancer. European Journal of Cancer, 1993, 29, S6-S8.	2.8	122
52	Limited Efficacy of Interferon- $\gamma$ and Vinblastine as Second Line Biochemotherapy Regimen in Patients with Progressive Metastatic Renal Cell Carcinoma. Cancer Biotherapy, 1993, 8, 301-306.	0.5	6